Gravity Analytica

Vigil Neuroscience to Present at Upcoming Investor Conferences

VIGL 11.12.2024

SERA-AI Powered Highlights

Date of Upcoming Event:2024-11-18

Name of Upcoming Event:Stifel 2024 Healthcare Conference

Date of Upcoming Event:2024-11-20

Name of Upcoming Event:Jefferies London Healthcare Conference

Full Press Release SEC Filings Our VIGL Tweets

About Gravity Analytica

Recent Filings

PDF Version

WATERTOWN, Mass., Nov. 12, 2024 (GLOBE NEWSWIRE) --Vigil Neuroscience, Inc.(Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced that management will be presenting at the following conferences in November:

Stifel 2024 Healthcare ConferenceFormat: Fireside ChatDate/Time: Monday, November 18th at 4:45 p.m. ET

Jefferies London Healthcare ConferenceFormat: Fireside ChatDate/Time: Wednesday, November 20th at 8:30 a.m. GMT

The webcasts will also be available on the Company’s website in the “Investors” section under“Events & Presentations.” Archived webcasts will be available for approximately 90 days following the presentation.

About Vigil Neuroscience

Vigil Neuroscience is a clinical-stage biotechnology company focused on developing treatments for both rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Vigil is utilizing the tools of modern neuroscience drug development across multiple therapeutic modalities in its efforts to develop precision-based therapies to improve the lives of patients and their families. Iluzanebart, Vigil’s lead clinical candidate, is a fully human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 (TREM2) in people with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease. Vigil is also developing VG-3927, a novel small molecule TREM2 agonist, to treat common neurodegenerative diseases associated with microglial dysfunction, with an initial focus on Alzheimer’s disease (AD) patients, including some who carry TREM2 and other disease-associated variants.

Internet Posting of Information

Vigil Neuroscience routinely posts information that may be important to investors in the “Investors” section of its website athttps://www.vigilneuro.com. The company encourages investors and potential investors to consult our website regularly for important information about Vigil Neuroscience.

Investor Contact:Leah GibsonVice President, Investor Relations & Corporate CommunicationsVigil Neuroscience, Inc.lgibson@vigilneuro.com

Media Contact:Megan McGrathCTD Comms, LLCmegan@ctdcomms.com

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com